Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1447 Clinicopathologic Features, Management and Outcome of Neuroendocrine Tumors (NETs) in MEN1: The Verona Multidisciplinary PlaNET Group

Introduction: Gastroenteropancreatic endocrine tumors (GEP-NETs) are a frequent manifestation of MEN1. They represent an important prognostic factor in these patients. There is still a debate on their management, mainly on surgical strategy, due to their multicentricity and high recurrence rate.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Cosaro E, Mella A, Cingarlini S, Grego E, Ortolani S,

Keywords: MEN1, GEP-NET, management,

#305 Risk Stratification Using Octreotide Test for Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results of Prospective Validation of the Test

Introduction: We recently demonstrated that a plasma CgA decrement >30% after octreotide s.c. injection is a simple criterion for treatment with Somatostatin analogues (SSA) of gastroenteropancreatic endocrine tumors.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Massironi S, Spampatti M, Rossi R, Conte D, Ciafardini C,

Keywords: gastroenteropancreatic neuroendocrine tumors (GEP-NETs), octreotide test (OT), prognosis ,

#272 Plasma Chromogranin A in Patients with MEN I and Pancreatic Endocrine Tumors

Introduction: Circulating chromogranin A(CgA) is considered a useful marker for gastroenteropancreatic endocrine tumors. Data on its pattern in MEN-1 patients with non-functioning pancreatic tumors(NFPT) are scant.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Rossi R, Massironi S, Spampatti M, Eller Vainicher C, Conte D,

Keywords: MEN-1, Chromogranin A (CgA), pancreatic endocrine tumors (PT), non-functioning pancreatic tumors (NFPT),

#210 Clinical Characteristics of the 5,160 Patients Included in the French Database of the French Endocrine Tumor Group (GTE)

Introduction: An endocrine tumor database was initiated in 2005 by the French endocrine tumor group (GTE). Today, it comprises 5,160 patients, 70% of whom were diagnosed from 2000.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Borson-Chazot F, Baudin E, Lombard C, Ruszniewski P, Niccoli P,

Keywords: gastroenteropancreatic endocrine tumor, database, clinical characteristics ,

#113 Prolonged cell survival in xenografts from human digestive endocrine tumors

Introduction: Gastroenteropancreatic endocrine tumors have the capacity to achieve very large tumor masses despite usually very low proliferative rates. This suggests that neoplastic endocrine cells may have long life spans, implying the development of specific mechanisms able to promote cell survival.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Poncet G

Authors: Poncet G, Lépinasse F, Hervieu V, Hommell J, Walter T,

Keywords: human grafted tumors, cell survival, morphological differentiation,